{"name":"Teclison Ltd.","slug":"teclison-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Regorafenib Pill","genericName":"Regorafenib Pill","slug":"regorafenib-pill","indication":"Other","status":"phase_2"},{"name":"TAS-102 pill","genericName":"TAS-102 pill","slug":"tas-102-pill","indication":"Other","status":"phase_2"},{"name":"TATE and pembrolizumab","genericName":"TATE and pembrolizumab","slug":"tate-and-pembrolizumab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Regorafenib Pill","genericName":"Regorafenib Pill","slug":"regorafenib-pill","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TAS-102 pill","genericName":"TAS-102 pill","slug":"tas-102-pill","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TATE and pembrolizumab","genericName":"TATE and pembrolizumab","slug":"tate-and-pembrolizumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRnVKekhWaTlkVHNmWUJMX0lIRUtPYlg1YU9XcENtOGZUQnhNaDd5YndpUnpZb2ZFdWU4SEtLZ1o4akltakx4Yi1oLS1RRVFidDdvN2hBVkhNWXo4X3pXMmdFdXpHT21VcDkzNHQtTWMweHVra0pvV0pkV3lCZ0hYUnV4dEJUN1ZCVFhuaGpiOVRDa3RCY2I1MWdNOXFFRndyaTI1MzVTbk5Mai1YN2pZRnVUWTIxRzhVckUzaHBSY2otUHBEc09SYkYzR3IwQ2wzNnpCYVhfRUdBUQ?oc=5","date":"2026-01-06","type":"pipeline","source":"GlobeNewswire","summary":"Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium - GlobeNewswire","headline":"Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQNDVrNmltTWZsaHhyLUdadzJDVktkWW8xYmJCNlNQQUkteHNkZlROMFBoNkdnN0IyRkJnTzh5Wjd3OWl6Q2NWa3l5Y1dtU1FHMFY0eVFzLXNPTUhBSktKcTZFcE9oNkxVZUxwSUJlSnRlM3BvaTlLSlUwbjR6akIyZy1OcTNWYUxGb3FqLUp2TFZXdk9YU21DYXFvanBTVXNna2xDQUVWT09JS29yYmpucjUwSWZmbVZWUFNkN0Z4cDQ5b09fQUtydzJ1MA?oc=5","date":"2025-03-20","type":"pipeline","source":"GlobeNewswire","summary":"Teclison, Inc. to Participate in Upcoming Investor Conference - GlobeNewswire","headline":"Teclison, Inc. to Participate in Upcoming Investor Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPN0hNQkNaSE5SbGtYTDRNbmY4OWV3ODJlb1ZFZW1jWW5zSklGWEtDOS1mYUJFUHdWMGxyLTN2ZDR4aFB2c0tLNnFRQ2lZTGJ6aGViRWRWT0lPRVctLVBGYzEzdFU5RTFsLWtoUW1CU2ZqUkMzQnFNVTk3bmxZZWhCQnhaMW1wdkhrSENYWC1VaUQ2a1V1NW1CYWJMbmhpUU1TenY3NjVRWW5JZUF3d25WaDZKZmhQMVN2UjF6RTluaUY4dVJGelo3N2huRlJ2b1BKRHpIVXltc3dLODNPNkt0bGN3RGg4WGdtTjU4QUdDNm9rTGhtVVd3SjB1QzdPemNKbXMzV3pSN19handVUjgzN0laVVpQNFF2N2p4dWtvcE8zd01hZmJzekZvMDA4YkVjNFlB?oc=5","date":"2024-07-09","type":"pipeline","source":"PR Newswire","summary":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca - PR Newswire","headline":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNOGd4bmRrUmQzUEpLV1NTSk1UZDYyXzFmemhHTHE3N3JyN2xuYkNIUlQ0a3VaM3NaWTNxS2ZQQmFuTS10RHVkQzZ0WGVHc3I2eDl0NFlpMUJMaXZ0WW1sUzdoa2pGNDlvN1NmdjF2RWp0UVhaRXB2bmFudHRfWmRHek1VUS1MXzJFa2ZfaGhXc2xpWlMya3c?oc=5","date":"2022-03-01","type":"pipeline","source":"BioWorld News","summary":"Teclison raises $5.9M to advance solid tumor program - BioWorld News","headline":"Teclison raises $5.9M to advance solid tumor program","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}